Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05279053 · ClinicalTrials.gov registry record
Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers
A clinical trial, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- 58
- Enrollment target
NCT05279053 is a clinical trial that has completed, run by University of California, Los Angeles. The registered enrollment target is 58 participants.
The verdict
NCT05279053 has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- 58 participants
- Enrollment target
Study Summary
The proposed study evaluated sex differences in glutamate (Glu), with a focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, as well as how it is influenced by sex (males vs. females), smoking state (overnight abstinent vs. sated), and circulating ovarian hormones (estrogen and progesterone) in women. Glu was measured in the entire brain with special focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, all of which have been implicated in tobacco withdrawal, using an echo-planar spectroscopic imaging (EPSI) variant of magnetic resonance spectroscopy (MRS). Serum ovarian hormones (estrogen and progesterone) were measured for female participants to determine relationships between brain Glu and this hormone. Glu was be measured in smokers after overnight (\~12 h) abstinence and after participants smoked the first cigarette of the day.
Interventions
- BEHAVIORAL Abstinence and Smoking
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2023-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05279053
The ClinicalTrials.gov registry entry for NCT05279053 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abstinence and Smoking is the first listed.
NCT05279053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05279053 about?
NCT05279053 is a clinical study titled "Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers". The proposed study evaluated sex differences in glutamate (Glu), with a focus on the dorsal anterior cingulate cortex (dACC), anterior insula, and thalamus, as well as how it is influenced by sex (males vs. females), smoking state (overnight abstinent vs. sated), and circulating ovarian hormones (es...
What is the current status of trial NCT05279053?
This trial is currently completed. The enrollment target is 58 participants. The study started on 2021-04-01. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT05279053?
The interventions under investigation include: Abstinence and Smoking (BEHAVIORAL).
Who is sponsoring clinical trial NCT05279053?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.